Publications by authors named "Claudio D Schteingart"

Claim this Profile
D
Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders.
Stephanie Maciuba, Gregory D Bowden, Harrison J Stratton, Kazimierz Wisniewski, Claudio D Schteingart

MAbs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms.
Elizabeth A McCarthy, Daniel Dischino, Caroline Maguire, Silvia Leon, Rajae Talbi, Claudio D Schteingart

J Clin Endocrinol Metab· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.
Diane M Hargrove, Sudarkodi Alagarsamy, Glenn Croston, Régent Laporte, Steve Qi, Claudio D Schteingart

J Pharmacol Exp Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent, Selective, and Short-Acting Peptidic V Receptor Agonists.
Kazimierz Wiśniewski, Steve Qi, John Kraus, Brian Ly, Karthik Srinivasan, Claudio D Schteingart

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.
Kazimierz Wiśniewski, Javier Sueiras-Diaz, Guangcheng Jiang, Robert Galyean, Mark Lu, Claudio D Schteingart

J Med Chem· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.
Marc O Maybauer, Dirk M Maybauer, Perenlei Enkhbaatar, Régent Laporte, Halina Wiśniewska, Claudio D Schteingart

Crit Care Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New, potent, and selective peptidic oxytocin receptor agonists.
Kazimierz Wiśniewski, Sudarkodi Alagarsamy, Robert Galyean, Hiroe Tariga, Dorain Thompson, Claudio D Schteingart

J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the mechanism of degradation of oxytocin and its analogues in aqueous solution.
Kazimierz Wiśniewski, Jens Finnman, Marion Flipo, Robert Galyean, Claudio D Schteingart

Biopolymers· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.
Sebastian Rehberg, Perenlei Enkhbaatar, Janina Rehberg, Erin La, Nicky Ferdyan, Claudio D Schteingart

Crit Care Med· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New, potent, selective, and short-acting peptidic V1a receptor agonists.
Kazimierz Wisniewski, Robert Galyean, Hiroe Tariga, Sudarkodi Alagarsamy, Glenn Croston, Claudio D Schteingart

J Med Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
Régent Laporte, Arash Kohan, Joshua Heitzmann, Halina Wisniewska, Jeannine Toy, Claudio D Schteingart

J Pharmacol Exp Ther· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and in vitro pharmacological profile of potent and selective peptidic V1a receptor agonists.
Kazimierz Wisniewski, Robert Galyean, Hiroe Taki, Sudar Alagarsamy, Glenn Croston, Claudio D Schteingart

Adv Exp Med Biol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel bile acid in swans, tree ducks, and geese: 3alpha,7alpha,15alpha-trihydroxy-5beta-cholan-24-oic acid.
Genta Kakiyama, Takashi Iida, Takaaki Goto, Nariyasu Mano, Junichi Goto, Claudio D Schteingart

J Lipid Res· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.
Alan F Hofmann, Salam F Zakko, Marco Lira, Carlo Clerici, Lee R Hagey, Claudio D Schteingart

Hepatology· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
Todd W Vanderah, Claudio D Schteingart, Jerzy Trojnar, Jean-Louis Junien, Josephine Lai

J Pharmacol Exp Ther· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential bile acid metabolites. 25. Synthesis and chemical properties of stereoisomeric 3alpha,7alpha,16- and 3alpha,7alpha,15-trihydroxy-5beta-cholan-24-oic acids.
Takashi Iida, Masahiro Hikosaka, Genta Kakiyama, Keisuke Shiraishi, Claudio D Schteingart

Chem Pharm Bull (Tokyo)· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis